Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
65 results about "Anxiolytic" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
An anxiolytic (also antipanic or antianxiety agent) is a medication, or other intervention, that inhibits anxiety. This effect is in contrast to anxiogenic agents, which increase anxiety. Together these categories of psychoactive compounds or interventions may be referred to as anxiotropic compounds or agents. Some recreational drugs such as alcohol induce anxiolysis initially; however, studies show that many of these drugs are anxiogenic. Anxiolytic medications have been used for the treatment of anxiety disorder and its related psychological and physical symptoms. Light therapy and other interventions have also been found to have an anxiolytic effect.
Pain relief lollipop compositions and methods
InactiveUS20090191257A1Without pain and invasivenessFast pain reliefOrganic active ingredientsNervous disorderGabapentinOpioid Agonist
A pain relief lollipop comprises a candy matrix comprising (a) an opioid agonist, (b) an N-methyl-D-aspartate receptor antagonist different from the opioid agonist, (c) gabapentin, or a pharmaceutically acceptable salt thereof, and, optionally, a muscle relaxant, sedative, anxiolytic, and / or antidepressant. A patient can self-administer small amounts of the pain relief drug as needed by simply licking or sucking on the lollipop in response to his subjective experience of pain.
Owner:INNOVATIVE PHARMA
Antianxiety drugs and a method of screening the same
InactiveUS20070160538A1Alleviate and eliminate anxietyNervous disorderPeptide/protein ingredientsAnti-Anxiety EffectOREXIN A RECEPTOR
An anxiolytic drug of the invention comprises an orexin receptor antagonist, a pharmacologically acceptable salt thereof, or a solvate thereof as an active ingredient. A method for screening a compound having an anxiolytic action of the invention comprises a step of using orexin-A.
Owner:EISIA R&D MANAGEMENT CO LTD
Pharmaceutical compositions containing alpha3beta4 nicotinic receptor antagonists and methods of their use
InactiveUS20030199496A1Relief the painIncreased dopamineBiocidePeptide/protein ingredientsAntiepileptic drugAmphetamine use
A pharmaceutical composition comprising an .alpha.3.beta.4 nicotinic receptor antagonist effective to diminish the brain-derived feeling of pleasure due to increased dopamine in the pleasure-reward center of the brain typically associated with administration of an opioid agonist analgesic, a muscle relaxant, an anti-seizure medication, an anxiolytic drug, an amphetamine, a central nervous system stimulant, a tetrahydrocannabinol or that associated with an otherwise pleasurable or self-reinforcing behavior.
Owner:SIMON DAVID LEW
Radix Morindae officinalis extract, preparation method and applications thereof
The invention provides a Morinda officinalis extractive and a preparation method and an application. The invention provides a preparation method of an extract from a traditional Chinese medicine Radix Morindae officinalis. The invention provides preparation methods and structures of 12 new compounds in the extract (such as synanthrin type 10-21 polysaccharide and the like), and the molecular connection mode is as follows: alpha-D-glucopyranose-(1->2)-[beta-D-fructofuranose-(1->2)]8-19-beta-D-fructofuranose. The invention provides methods for preparing these compounds from Helianthus tuberosus, yacon and other plants. The invention provides a method for preparing the extract into a medicinal composition. The invention also provides applications of the extract used as an antidepressant and an anxiolytic.
Owner:佗林医药(青岛)有限公司
Method of treating an anxiety disorder
Anxiety disorders, such as panic disorder, agoraphobia, obsessive-compulsive disorder, social phobia, post-traumatic stress disorder, generalized anxiety disorder, specific phobia, or the like, are treated by administering an effective amount of at least one adenosine A2A receptor antagonist to a patient in need thereof, optionally in combination with an anxiolytic(s) other than the adenosine A2A receptor antagonist.
Owner:KYOWA HAKKO KIRIN CO LTD
Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
Owner:JANSSEN PHARMA NV
Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-alpha]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
The invention discloses N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazole-[1,5-α]-pyrimidin-7-yl}phenyl)acetamide (compound ( 1)), and their use as sedative-hypnotics, anxiolytics, anticonvulsants and skeletal muscle relaxants. At the same time, methods for preparing the substance and related compositions are also disclosed, especially for the treatment of insomnia. And provides the exceptional physical and thermal stability possessed by the Form I polymorph. Type II polymorphs are also contemplated.
![Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-alpha]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto](https://images-eureka.patsnap.com/patent_img/fe5cdd4d-2af8-4f4e-8238-58deb8d51f2f/A0081315800441.PNG "Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-alpha]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto")
![Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-alpha]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto](https://images-eureka.patsnap.com/patent_img/fe5cdd4d-2af8-4f4e-8238-58deb8d51f2f/A0081315800442.PNG "Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-alpha]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto")
![Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-alpha]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto](https://images-eureka.patsnap.com/patent_img/fe5cdd4d-2af8-4f4e-8238-58deb8d51f2f/A0081315800451.PNG "Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-alpha]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto")
Owner:NEUROCRINE BIOSCI INC
Anti-anxiety medicine by using rheum officinate root extract as active ingredient, and method and application thereof
The invention provides to an anti-anxiety medicine by using a rheum officinate root extract as an active ingredient. The anti-anxiety medicine uses the rheum officinate root extract as the active ingredient and can be made into various oral administration formulations such as tablet, granules, capsule, oral liquor, etc.; other components and supplementary materials can be added to form a compound preparation; and the anti-anxiety medicine has evident anti-anxiety effect and can be used for health and treatment of anxiety disorder. Moreover, the invention further provides health food prepared from the rheum officinate root extract and food additives, and preparation methods of the medicine and the food.
Owner:KUNMING INST OF BOTANY - CHINESE ACAD OF SCI
Application of P2X2 receptor agonist or opening agent in preparation of anti-depression or anti-anxiety drugs
ActiveCN103251951ASmall side effectsGood effectOrganic active ingredientsNervous disorderANXIETY COMPLEXAnti-Anxiety Effect
The invention discloses an application of a P2X2 receptor agonist or a P2X2 receptor opening agent in preparation of anti-depression or anti-anxiety drugs. According to the present invention, experiment research results confirm that: the P2X2 receptor agonist or the P2X2 receptor opening agent has an anti-depression and / or anti-anxiety effect, such that the P2X2 receptor agonist or the P2X2 receptor opening agent can be used for preparing anti-depression or anti-anxiety drugs, and can be adopted to screen prevention and treatment target points of anti-depression and / or anti-anxiety drugs and screen early stage pre-warning and clinical diagnostic reagents of depression and / or anxiety so as to provide broad application prospects.
Owner:誉神(广州)医学科技有限公司
Murraya paniculata leaf and application of mono compound in preparation of sedative and hypnotic drugs
The invention relates to the field of medicine and discloses a Murraya paniculata leaf, a Murraya paniculata leaf extractive and new biological activity of part of a flavonoid mono compound extracted from Murraya paniculata leaves, namely discloses a Murraya paniculata leaf, a Murraya paniculata leaf extractive and the use of part of a flavonoid mono compound extracted from Murraya paniculata leaves in preparation of sedative and hypnotic drugs, anxiolytic drugs, anticonvulsive drugs or antimanic drugs, in particular to the use in preparation of sedative and hypnotic drugs.
Owner:长春瑞德医药科技有限公司 +1
Compositions and methods comprising kava and anti-anxiety compounds
InactiveUS20050069596A1Reduce morbidityEnhancement of desired physiologicalBiocideOrganic chemistryRecurrent anxietyKava extract
The present invention comprises compositions comprising combinations of kava extract compositions in combination with one or more anxiolytics and methods for treating conditions related to the various anxiety disorders comprising administering the compositions of the present invention. The invention further provides methods for enhancing the therapeutic activity of an anxiolytic comprising administering the anxiolyitc in combination with extract of Piper methysticin.
Owner:HERBALSCIENCE NUTRACEUTICALS INC
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
InactiveUS20100331363A1Avoid cell deathIncreased insulin secretionBiocideNervous disorderAntioxidantDepressant
Methods and pharmaceutical compositions comprising a low dose of a farnesyl transferase inhibitor useful in the treatment of proteinopathies are provided. These low doses are below the doses used in oncological treatments for which these compounds were initially designed. The treatment includes administering to a subject an amount of a farnesyl transferase inhibitor, wherein the amount administered is sufficient to cause an improvement in mitochondrial health in said subject. Treatments in accordance with the present invention may also include an acetylcholinesterase inhibitor, an activator of neurotrophic receptors, an NMDA anatagonist, an amyloid deposit inhibitor, an antipsychotic agent, an antidepressant, an anxiolytic, or an antioxidant.
Owner:ASTRAZENECA AB
Composition for treatment of nicotine addiction containing a nicotine receptor antagonist and an anti-depressant of anti-anxiety drug
InactiveCN1280505ANervous disorderAmine active ingredientsDrug withdrawal symptomsNK1 receptor antagonist
The present invention encompasses methods of treating patients for tobacco addiction and nicotine addiction, for palliating the effects of nicotine withdrawal, for providing or facilitating the effects of smoking cessation therapies and as long-term smoking cessation maintenance therapy. The invention also includes related pharmaceutical compositions comprising nicotine receptor antagonists and either an anti-depressant or an anti-anxiety drug. Specific combinations of drugs (mecamylamine HCl and bupropion HCl) as well as mecamylamine in combination with certain drug classes (e.g., anti-anxiety drugs and anti-depressants) comprise the pharmaceutical compositions disclosed. These compositions are also contemplated for use in the treatment of cocaine addiction and the treatment of alcohol dependence.
Owner:CARY PHARMA
Imidazo[1,2-a] pyridine anxiolytics
![Imidazo[1,2-a] pyridine anxiolytics](https://images-eureka.patsnap.com/patent_img/debbd268-8b43-40c2-8d03-8b4d19aba7af/US07148353-20061212-D00001.png "Imidazo[1,2-a] pyridine anxiolytics")
![Imidazo[1,2-a] pyridine anxiolytics](https://images-eureka.patsnap.com/patent_img/debbd268-8b43-40c2-8d03-8b4d19aba7af/US07148353-20061212-D00002.png "Imidazo[1,2-a] pyridine anxiolytics")
![Imidazo[1,2-a] pyridine anxiolytics](https://images-eureka.patsnap.com/patent_img/debbd268-8b43-40c2-8d03-8b4d19aba7af/US07148353-20061212-D00003.png "Imidazo[1,2-a] pyridine anxiolytics")
Owner:SEPACOR INC
Method of treating an anxiety disorder
Owner:KYOWA HAKKO KIRIN CO LTD
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
InactiveUS20110060005A1Avoid cell deathIncreased insulin secretionBiocideNervous disorderAntioxidantMITOCHONDRIAL PHERS
Methods and pharmaceutical compositions comprising a low dose of a farnesyl transferase inhibitor useful in the treatment of proteinopathies and mitochondrial disorders are provided. These low doses are below the doses used in oncological treatments for which these compounds were initially designed. The treatment includes administering to a subject an amount of a farnesyl transferase inhibitor, wherein the amount administered is sufficient to stimulate mitophagy in said subject. Treatments in accordance with the present invention may also include an acetylcholinesterase inhibitor, an activator of neurotrophic receptors, an NMDA anatagonist, an amyloid deposit inhibitor, an antipsychotic agent, an antidepressant, an anxiolytic, or an antioxidant.
Owner:ASTRAZENECA AB
Compositions For The Treatment of Central Nervous System Disorders Including Depression Employing Novel Drug Combination Therapy To Reduce Suicidality In Patients
Described herein are novel methods and formulations for reducing suicidality in human subjects. Such formulations and methods are a combination of lithium and one or more other CNS therapeutic agents such as anti-depressant, mood-stabilizing, anxiolytic, anticonvulsant, antipsychotic, anti-addictive, and appetite suppressant drugs.
Owner:KHAN ARIFULLA
Pharmaceutical preparations containing bilobalide for the treatment of tension and anxiety
PCT No. PCT / EP92 / 02981 Sec. 371 Date Jul. 14, 1994 Sec. 102(e) Date Jul. 14, 1994 PCT Filed Dec. 22, 1992 PCT Pub. No. WO93 / 12784 PCT Pub. Date Jul. 8, 1993The invention suggests a novel medical use of pure bilobalide or Ginkgo biloba extract with an increased bilobalide content as an anxiolytic or antidepressant.
Owner:DR VILMAR SHVABE GMBKH EHND KO KG
Treatment of proteinopathies using a farnesyl transferase inhibitor
InactiveUS20100160372A1Reduces α-synuclein levelLess inclusionBiocideSenses disorderAntioxidantDepressant
Methods and pharmaceutical compositions comprising a low dose of a farnesyl transferase inhibitor useful in the treatment of proteinopathies are provided. These low doses are below the doses used in oncological treatments for which these compounds were initially designed. The treatment includes administering to a subject in need thereof a therapeutically effective amount of a farnesyl transferase inhibitor, wherein the amount is effective to inhibit the farnesylation of a non-Ras FTase substrate involved in the autophagy pathway without substantially affecting the farnesylation of Ras or other oncology related substrates. Treatments in accordance with the present invention may also include an acetylcholinesterase inhibitor, an activator of neurotrophic receptors, an NMDA antagonist, an amyloid deposit inhibitor, an antipsychotic agent, an antidepressant, an anxiolytic, or an antioxidant.
Owner:ASTRAZENECA AB
Application of coptis and alkaloid thereof in preparation of anti-anxiety medicament
The invention relates to application of coptis and alkaloid thereof in preparation of an anti-anxiety medicament. The problem that the coptis or the alkaloid is applied in preparation of the anti-anxiety medicament can be effectively solved. The invention adopts the technical scheme that: the coptis is decocted into coptis decoction by adding water, or the coptis is extracted by using ethanol, then coptis alkaloid is prepared by using water bath, and the coptis water bath fluid or the coptis alkaloid is subjected to mouse cross maze or light and dark box passing experiments; and the experiment results show that the coptis and the alkaloid thereof have anti-anxiety effect. The application can expand the medicinal value of the coptis, and is an innovation on the anti-anxiety medicament.
Owner:HENAN UNIV OF CHINESE MEDICINE
![Imidazo[1,2-a] pyridine anxiolytics](https://images-eureka.patsnap.com/patent_img/90ee38a5-0c0a-4775-b01f-17cd511e401e/US20070043074A1-20070222-D00001.png "Imidazo[1,2-a] pyridine anxiolytics")
![Imidazo[1,2-a] pyridine anxiolytics](https://images-eureka.patsnap.com/patent_img/90ee38a5-0c0a-4775-b01f-17cd511e401e/US20070043074A1-20070222-D00002.png "Imidazo[1,2-a] pyridine anxiolytics")
![Imidazo[1,2-a] pyridine anxiolytics](https://images-eureka.patsnap.com/patent_img/90ee38a5-0c0a-4775-b01f-17cd511e401e/US20070043074A1-20070222-D00003.png "Imidazo[1,2-a] pyridine anxiolytics")
Application of substituted cinnamamide derivative to preparation of anxiolytic medicine
ActiveCN107011313AImprove anxietyImprove sleep disordersNervous disorderOrganic chemistryCyclohexylaminesBULK ACTIVE INGREDIENT
Owner:TIANJIN TASLY PHARMA CO LTD
Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-alpha]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-α]-pyrimidin-7-yl}phenyl)acetamide (Compound 1), and use of the same as a sedative-hypnotic, anxiolytic, anticonvulsant, and skeletal muscle relaxant agent. Processes for making the same, as well as related compositions and methods are also disclosed, particularly with regard to treatment of insomnia. A polymorph Form I possessing exception physical and heat stability is provided. A polymorph Form II:
![Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-alpha]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto](https://images-eureka.patsnap.com/patent_img/204fe2ef-ff7f-4e7c-b30e-2121b4f11353/US06958342-20051025-D00001.png "Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-alpha]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto")
![Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-alpha]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto](https://images-eureka.patsnap.com/patent_img/204fe2ef-ff7f-4e7c-b30e-2121b4f11353/US06958342-20051025-D00002.png "Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-alpha]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto")
![Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-alpha]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto](https://images-eureka.patsnap.com/patent_img/204fe2ef-ff7f-4e7c-b30e-2121b4f11353/US06958342-20051025-D00003.png "Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-alpha]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto")
Owner:NEUROCRINE BIOSCI INC
Nociceptin-based analgesics
The invention relates to a family of hexapeptide compounds exhibiting activity with regard to the ORL-1 receptor. The compounds share a general formula of Arg-Tyr-Tyr-Arg-Trp-Arg, and may be constructed having modifications or substitutions at any position, and may include modifications of the amino- and carboxy-termini of the hexapeptide. These compounds include agents exhibiting agonist activity and antagonist activity when exposed to the human ORL-1 receptor. As such, the hexapeptides may be useful as analgesics, anxiolytics, diuretics, and anti-cancer agents.
Owner:SYNVAX
Method for screening for compounds as potential sedatives or anxiolytics
InactiveUS20060013770A1Easy to measureOrganic active ingredientsNervous disorderMuscle relaxationPhysiology
The present invention relates to a method for screening a chemical compound for its potential as a sedative or anxiolytica. The invention also relates to a drug development method and to the use of a compound as identified by the screening method for the treatment, prevention or alleviation of anxiety, for inducing anaesthesia, pre-anaesthesia, muscle relaxation, or sedation, or for treatment, prevention or alleviation of fever cramps or status epilepticus in a subject.
Owner:NEUROSEARCH AS
Assay for screening antidepressants
InactiveUS20110296540A1Reduce expressionIncrease heightMicrobiological testing/measurementBiological testingNon respondersArtificial cerebrospinal fluid
This invention provides a method for identifying a small molecule as an antidepressant, a method for identifying a small molecule as an anxiolytic, and a method for identifying a small molecule as able to increase dendritic arborization, decrease expression of an immaturity marker, increase expression of a maturity marker, or enhance artificial cerebrospinal fluid-type long-term potentiation in central nervous system. This invention also provides a transgenic mouse model for SSRI-non-responders.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Application of NADPH in preparation of anti-anxiety drugs
ActiveCN107213159AAnti-anxietyLower anxiety levelsOrganic active ingredientsNervous disorderGeneralized anxiety disorderAnti-Anxiety Effect
The invention belongs to the field of drugs or health products and particularly relates to an application of NADPH in preparation of anti-anxiety drugs. The research finds that the NADPH is capable of significantly improving the exploration interest, significantly reducing the anxiety level of a rat and reversing anxiety behaviors caused by chronic stress. The results show that the NADPH has an anti-anxiety effect, and can be used as a potential drug for preventing or treating generalized anxiety disorder.
Owner:山东蓝康生物科技有限公司
Anxiolytic Marcgraviaceae compositions containing betulinic acid, betulinic acid derivatives, and methods
Pharmaceutical compositions for preventing or treating anxiety, comprising betulinic acid or derivatives thereof are provided. Methods for preventing or treating anxiety with betulinic acid or derivatives thereof are also provided. The invention further provides betulinic-acid containing preparations of plants of the family Marcgraviaceae having anxiolytic activity and methods for making such extracts and using them to prevent or treat anxiety in a subject.
Owner:UNIVERSITY OF OTTAWA
Morphinan derivative
ActiveUS10442802B2Good effectSuppression of gastrointestinal motilityOrganic active ingredientsSenses disorderHydrogenMorphine
A morphinan derivative represented by the following general formula (I):(wherein R1 represents hydrogen, C1-10 alkyl, cycloalkylalkyl where the cycloalkyl moiety has 3 to 6 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms, etc.,R2 represents heterocyclic ring containing 1 to 4 heteroatoms selected from N, O and S and at least one carbon atom as ring-constituting atoms, containing at least one set of adjacent ring-constituting atoms bound by a double bond, and further substituted with at least one oxo group,Y binds to a carbon atom as a ring-constituting atom of R2,R3, R4, and R5 represent hydrogen; hydroxy, etc.,R6a and R6b represent hydrogen, etc.,R7 and R8 represent hydrogen, etc.,R9 and R10, which are the same or different, represent hydrogen, etc.,X represents O or CH2, andY represents C(═O)),a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an anxiolytic drug, antidepressant, etc.
Owner:NIPPON CHEMIPHAR CO LTD
Mixed inhibitors of aminopeptidase n and of neprilysine
Mixed inhibitors of aminopeptidase N and of neprilysine are described. Pharmaceutical compositions containing at least one of these compounds, used alone or in combination with morphine and derivatives thereof, endocannabinoids and inhibitors of the metabolism thereof, GABA derivatives such as gabapentin or pregabalin, duloxetine or methadone, can be used as an analgesic, anxiolytic, antidepressant or anti-inflammatory.
Owner:智腾大中华区有限公司
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com